Skip to main content
DFTX
NASDAQ Life Sciences

Definium Therapeutics Reports Positive Phase 3 Results for DT120 ODT in Major Depressive Disorder

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$33.02
Mkt Cap
$2.67B
52W Low
$6.345
52W High
$26.25
52W Position info
420% above low
Off High info
at 52W high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

DFTX has more than doubled off its 52-week low of $6.345.

Summary

Definium Therapeutics announced highly positive topline results from its Phase 3 EMERGE study of DT120 ODT for Major Depressive Disorder, meeting all primary and key secondary endpoints with rapid and durable efficacy and a favorable safety profile.


Key Events · Product Development and Regulatory · DFTX

  • Positive Phase 3 EMERGE Study Results

    Definium Therapeutics announced positive topline data from its Phase 3 EMERGE study of DT120 ODT for Major Depressive Disorder (MDD), meeting its primary and all key secondary efficacy endpoints.

  • Significant Efficacy in MDD

    The study showed an 8.1 point placebo-adjusted change from baseline in MADRS total score at Week 6 (primary endpoint, p<0.0001) and a 7.3 point change at Week 12 (secondary endpoint, p<0.0001), demonstrating rapid and durable relief.

  • Favorable Safety Profile

    DT120 ODT was generally well tolerated, with 99% of adverse events being mild to moderate. No serious adverse events or suicidality signals were identified.

  • Efficient Dosing Session

    The average time for participants to clear the End of Session Checklist (EoSC) was 5.8 hours, with all participants clearing by 8 hours, supporting its potential for clinical practice.


Analysis · DFTX · Life Sciences

Definium Therapeutics announced highly positive topline results from its Phase 3 EMERGE study for DT120 ODT in Major Depressive Disorder (MDD). The drug met all primary and key secondary efficacy endpoints, demonstrating rapid, robust, and durable relief. This is a critical de-risking event for the company, validating its lead asset in a large market with significant unmet needs. The favorable safety profile and efficient dosing session further enhance its commercial potential, positioning DT120 ODT as a potential best-in-class treatment and a new paradigm for MDD management. This news, coming as the stock trades near its 52-week high, reinforces strong investor confidence in the company's pipeline.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DFTX was trading at $33.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $6.35 to $26.25. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DFTX - Latest Insights

DFTX
Nov 09, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $36.00
Real-time Price: $29.48 info
Change: -$6.52 (-18%) info
Market Cap: $4.036B info
DFTX
Nov 09, 2026, 4:01 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $35.36
Real-time Price: $29.48 info
Change: -$5.87 (-17%) info
Market Cap: $4.036B info
DFTX
Sep 14, 2026, 8:02 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $45.00
Real-time Price: $29.48 info
Change: -$15.52 (-34%) info
Market Cap: $4.036B info
DFTX
Sep 14, 2026, 7:00 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $41.46
Real-time Price: $29.48 info
Change: -$11.98 (-29%) info
Market Cap: $4.036B info
DFTX
Sep 08, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $39.39
Real-time Price: $29.48 info
Change: -$9.91 (-25%) info
Market Cap: $4.036B info